A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Genentech, Inc.
National Cancer Institute (NCI)
Nammi Therapeutics Inc
National Cancer Institute (NCI)
SystImmune Inc.
Merck Sharp & Dohme LLC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Myeloid Therapeutics
Jonsson Comprehensive Cancer Center
Avacta Life Sciences Ltd
Innate Pharma
Dren Bio
Incyte Corporation
Pfizer
Tempest Therapeutics
Nurix Therapeutics, Inc.
Pfizer
Exelixis
Jonsson Comprehensive Cancer Center
Xencor, Inc.
University of Virginia
Incyte Corporation
NextPoint Therapeutics, Inc.
Monopar Therapeutics
Monopar Therapeutics
Checkpoint Therapeutics, Inc.
Carisma Therapeutics Inc
Vincerx Pharma, Inc.
Molecular Templates, Inc.
Pfizer
Xencor, Inc.
Pliant Therapeutics, Inc.
Atreca, Inc.
University of Florida
Fate Therapeutics
Fate Therapeutics
Xencor, Inc.
Herlev Hospital
Xencor, Inc.
Ludwig Institute for Cancer Research
PACT Pharma, Inc.
EMD Serono
Incyte Corporation
Eisai Inc.
Incyte Corporation
Celgene
Merrimack Pharmaceuticals
Corcept Therapeutics